Spero Therapeutics Inc (SPRO) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access SPRO Annual Balance Sheets →
A period-by-period view of the balance sheet from Spero Therapeutics Inc to Jun 30 2025 helps clarify how Jun 30 2026's financial structure has changed over time.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent50.77
Cash & Short-term Investments50.00
Other Receivables0.00
Other Current Assets0.03
Prepaid Expense And Other Assets Current0.79
Total Current Assets51.58
Other Assets, Noncurrent1.18
Total Assets52.77
Liabilities
Accounts Payable, Current AC0.16
Accrued Royalties0.97
Other Liabilities, Current7.14
Taxes Payable, Current, Total0.16
Total Current Liabilities8.43
Other Long-term Debt, Noncurrent OT0.09
Total Long-term Debt0.09
Deferred Revenue, Noncurrent DE0.00
Other liabilities, Noncurrent0.04
Accrued Expenses And Other Current Liabilities3.14
Operating Lease Liability Noncurrent0.51
Total Liabilities8.56
Stockholders' Equity
Common Stock Value0.06
Additional Paid In Capital Common Stock511.97
Retained Earnings / Accumulated Deficit-467.82
Other Equity0.00
Common Stockholder's Equity44.20
Total Stockholder's Equity44.20
Liabilities & Stockholder's Equity52.77
4 historic quarters locked

Sign in to unlock the full Spero Therapeutics Inc balance sheet history.

About Spero Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-346795

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.